Identifying the tiny cells that causes AML to evade detection and survive
Despite current chemotherapy treatments, many people with acute myeloid leukaemia (AML) often see their disease return. Professor Tonks plans to investigate a new method that could help ensure all cancer cells are destroyed and the cancer is unable to come back.
The challenge
AML is an aggressive form of blood cancer and often develops quickly. Many people with AML receive chemotherapy treatment, which is extremely toxic with horrible side effects. Despite this treatment, people often see the disease return as a tiny population of cells called ‘stem cells’ go undetected and survive. These stem cells continue to divide and multiply, ultimately causing the cancer to return. Professor Tonks and his team want to find a way to detect these cells and find drugs which can kill them.
The project
In this pilot project, Professor Tonks and his team plan to investigate a new method so they can identify these tiny stem cells that go undetected before a patient receives chemotherapy. The project will ultimately allow the team to understand how many cells the team need so they can carry out these further tests. This means that other drugs could then be combined with the chemotherapy to target these tiny cells, so all the cancer cells are destroyed, and the cancer is unable to return.
The future
If successful, the team hope to use this knowledge to run further tests, to test how other drugs could then be combined with the chemotherapy to target these tiny cells, so all the cancer cells are destroyed, and the cancer is unable to return. The team also hope this method can be applied and help in the treatment of many other types of blood cancer, giving everyone the best possible chance of survival.
Funding
This project is part of the innovative pilot grant round.